The Medicines Company
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$23.1M
Doctors Paid
5,999
Transactions
22,838
2018 Total
$18.5M
Payment Breakdown by Category
Research$19.9M (86.2%)
Consulting$1.1M (4.7%)
Food & Beverage$490,284 (2.1%)
Travel$264,730 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $19.9M | 4,640 | 86.2% |
| Honoraria | $1.1M | 642 | 5.0% |
| Consulting Fee | $1.1M | 148 | 4.7% |
| Food and Beverage | $490,284 | 16,177 | 2.1% |
| Travel and Lodging | $264,730 | 1,017 | 1.1% |
| Education | $117,842 | 178 | 0.5% |
| Grant | $35,000 | 2 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $31,700 | 31 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,525 | 1 | 0.0% |
| Entertainment | $115.91 | 2 | 0.0% |
Payments by Type
Research
$19.9M
4,640 transactions
General
$3.2M
18,198 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol ORION-10 | $8.4M | 0 | 1,066 |
| A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease | $7.8M | 0 | 18 |
| INCLISIRAN FOR PARTICIPANTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL ORION-10 | $1.1M | 2 | 3,004 |
| Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia HeFH ORION-9 | $417,137 | 1 | 84 |
| PCSK9 ORION4 Ph3 Outcomes | $300,617 | 0 | 1 |
| Understanding the Longitudinal Clinical Effect and Resource Use of Managing Patients With Raised LDL-C and Preexisting Cardiovascular Disease The IMPRES Study | $201,000 | 0 | 3 |
| An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C ORION-3 | $186,841 | 0 | 45 |
| Understanding the Longitudinal Clinical Effect and Resource Use of Managing Patients With Raised LDL-C and Pre-existing Cardiovascular Disease | $150,000 | 0 | 2 |
| A RETROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE UTILIZATION, OUTCOMES, AND ADVERSE EVENTS IN PARTICIPANTS TREATED WITH ORBACTIV ORITAVANCIN FOR INFECTIONS CAUSED BY GRAM POSITIVE BACTERIA IN A REAL WORLD SETTING | $143,855 | 0 | 51 |
| EFFICACY, SAFETY, TOLERABILITY OF CARBAVANCE COMPARED TO BEST AVAILABLE THERAPY IN SERIOUS INFECTIONS DUE TO CARBAPENEM RESISTANT ENTEROBACTERIACEAE, IN ADULTS | $139,186 | 0 | 52 |
| Double-Blind, Randomized Study to Evaluate the Safety of either a Single IZOD-mg Intravenous IV Dose of OrbactivTM oritavancin and Placebo or two N Doses of OrbactivTM in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection ABSSSI | $129,596 | 0 | 3 |
| Comparative Efficacy of Oritavancin in the Rabbit Model of Treatment of Experimental Mcthicillin Resistant Staphylococcus aureus Endocarditis | $101,000 | 0 | 1 |
| MDCO-216 INFUSIONS LEADING TO CHANGES IN ATHEROSCLEROSIS A NOVEL THERAPY IN DEVELOPMENT TO IMPROVE CARDIOVASCULAR OUTCOMES - PROOF OF CONCEPT INTRAVASCULAR ULTRASOUND IVUS, LIPIDS, AND OTHER SURROGATE BIOMARKERS TRIAL | $97,143 | 1 | 5 |
| OPEN LABEL, DOSE-FINDING, PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF MEROPENEM-VABORBACTAM IN PEDIATRIC SUBJECTS WITH SERIOUS BACTERIAL INFECTIONS | $85,477 | 1 | 17 |
| Infusions Leading to Changes in Atherosclerosis A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound IVUS, Lipids, and Other Surrogate Biomarkers Trial | $69,138 | 0 | 2 |
| A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin lnfusions in Healthy Subjects | $61,337 | 0 | 1 |
| OPEN-LABEL, DOSE-FINDING, PHARMACOKINETICS, SAFETY AND TOLERABILITY STUDY OF ORITAVANCIN IN PEDIATRIC PATIENTS WITH SUSPECTED OR CONFIRMED BACTERIAL INFECTIONS | $37,293 | 1 | 11 |
| A STUDY OF MEROPENEM-VABORBACTAM VERSUS PIPERACILLINTAZOBACTAM IN PARTICIPANTS WITH HOSPITAL-ACQUIRED AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA | $36,562 | 1 | 7 |
| SAFETY AND CLINICAL UTILITY STUDY OF SSEC FENTANYL 40 MCG FOR ACUTE POST-OP PAIN MANAGEMENT IN PEDIATRIC PARTICIPANTS | $31,925 | 0 | 13 |
| Carbavance RPX2014RPX7009 Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae | $30,356 | 0 | 94 |
| Orbactiv Pre-Clinical US | $27,100 | 0 | 1 |
| Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia | $25,947 | 0 | 106 |
| Infusions Leading to changes in Atherosclerosis a Novel therapy in development to improve cardiovascular Outcomes Proof of concept IVUS, Lipids and Other surrogate biomarkers Trial | $20,906 | 0 | 2 |
| TREATMENT ON PLAQUE BURDEN IN SUBJECTS WITH A RECENT ACUTE CORONARY SYNDROME ACS | $20,700 | 0 | 1 |
| A multiple dose, dose-finding, placebo controlled, double blind, randomized trial to compare the effect of treatment on plaque burden as determined by intravascular ultrasound and evaluate the efcacy, safety, and tolerability of MDCO-216 given as multiple weekly infusions in subjects with a recent acute coronary syndrome event Milano DRIVE | $20,700 | 0 | 1 |
| ENDOvascular Interventions with AngioMAX The ENDOMAX Trial | $17,350 | 0 | 4 |
| Carotid with Bivalirudin Angioplasty COBRA study | $15,000 | 0 | 3 |
| SAFETY AND CLINICAL UTILITY STUDY OF SSEC FENTANYL 40 MCG FOR ACUTE POST-OP PAIN MANAGEMENT IN PEDIATRIC PATIENTS | $14,670 | 0 | 4 |
| In Vitro Compressive Strength Testing of Oritavancin Loaded Polymethylmethacrylate PMMA Beads | $10,190 | 0 | 2 |
| A RETROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE UTILIZATION, OUTCOMES, AND ADVERSE EVENTS IN PARTICIPANTS TREATED WITH MINOCIN MINOCYCLINE FOR INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA IN A REAL WORLD SETTING | $8,949 | 0 | 5 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Dr. John Marota, Phd Md, PHD MD | Anesthesiology | Boston, MA | $321,359 | $0 |
| Dr. Melvin Spigelman, M.d, M.D | Medical Oncology | Bronx, NY | $161,678 | $0 |
| Dr. Warren Joseph, Dpm, DPM | Primary Podiatric Medicine | Phoenix, AZ | $131,169 | $0 |
| Dino Delaportas, M.d, M.D | Infectious Disease | Bridgeport, WV | $105,091 | $0 |
| Dr. John Homan, Md, MD | Internal Medicine | Huntington Beach, CA | $93,886 | $0 |
| Dr. Marya Zilberberg, M.d, M.D | Pulmonary Disease | Leeds, MA | $78,400 | $0 |
| Jason Sniffen, Do, DO | Infectious Disease | Altamonte Springs, FL | $77,062 | $0 |
| Dr. Javeed Siddiqui, Md, Mph, MD, MPH | Infectious Disease | Roseville, CA | $70,500 | $0 |
| Markian Bochan, Md, MD | Infectious Disease | Carmel, IN | $63,750 | $0 |
| Dr. Andrew Dold, D.o, D.O | Infectious Disease | Dacula, GA | $59,473 | $0 |
| Bruce Friedman, M.d, M.D | Critical Care Medicine | Augusta, GA | $52,434 | $0 |
| Dr. Ali Hassoun, Md, MD | Infectious Disease | Huntsville, AL | $51,845 | $0 |
| Dr. Matthew Wikler, M.d, M.D | Infectious Disease | San Diego, CA | $46,800 | $0 |
| Dr. David Wu, M.d, M.D | Infectious Disease | West Chester, PA | $41,700 | $0 |
| Dr. Jeffery Alexander, Dpm, DPM | Podiatrist | Chicago, IL | $40,485 | $0 |
| Dr. Sarah Schlesinger, M.d, M.D | Immunopathology | New York, NY | $39,826 | $0 |
| Dr. William Denman, Md, MD | Anesthesiology | Boston, MA | $38,890 | $0 |
| Andrew Shorr, Md, MD | Pulmonary Disease | Washington, DC | $33,888 | $0 |
| Guillermo Padilla, M.d, M.D | Infectious Disease | Shreveport, LA | $29,598 | $0 |
| Unknown Provider | — | — | $28,800 | $0 |
| Dr. Thuan Le, M.d, M.D | Infectious Disease | Murrieta, CA | $27,680 | $0 |
| Dr. Tracy Cross, M.d, M.D | Surgery | Albany, KY | $25,436 | $0 |
| Joseph Answine, Md, MD | Anesthesiology | Mechanicsburg, PA | $24,911 | $0 |
| Dr. Alan Miller, M.d, M.D | Internal Medicine | Peachtree Corners, GA | $24,413 | $0 |
| Unknown Provider | — | — | $23,655 | $0 |
About The Medicines Company
The Medicines Company has made $23.1M in payments to 5,999 healthcare providers, recorded across 22,838 transactions in the CMS Open Payments database. In 2018, the company paid $18.5M. The top product by payment volume is ORBACTIV ($1.8M).
Payments were distributed across 126 medical specialties. The top specialty by payment amount is Infectious Disease ($1.0M to 767 doctors).
Payment categories include: Food & Beverage ($490,284), Consulting ($1.1M), Research ($19.9M), Travel & Lodging ($264,730).
The Medicines Company is associated with 5 products in the CMS Open Payments database, including ORBACTIV, VABOMERE, and MINOCIN IV.